RXi Takes License to Self-Delivering RNAi Agents, Ends RNAi Tech-License Deals with UMMS

According to RXi's top official, the company first acquired an option to the self-delivering technology because it "overlapped" with its own efforts to develop RNAi drugs that do not require a delivery vehicle.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories